FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
193.37M
422.49M
278.17M
225.88M
188.87M
203.34M
218.93M
235.7M
253.77M
273.22M
Operating Cash Flow
-213.79k
5.16M
11.95M
1.42M
-1.8M
2.07M
2.23M
2.4M
2.58M
2.78M
Cap Ex
-4.43M
-18.74M
-12.9M
-6.7M
-1.98M
-6.25M
-6.73M
-7.25M
-7.8M
-8.4M
Free Cash Flow
-4.64M
-13.58M
-948k
-5.28M
-3.78M
-4.19M
-4.51M
-4.85M
-5.22M
-5.62M
Wacc
13.54
13.54
13.54
13.54
13.54
Pv Lfcf
-3.69M
-3.5M
-3.31M
-3.14M
-2.98M
Sum Pv Lfcf
-16.62M
